Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 10;13(8):1719.
doi: 10.3390/life13081719.

Role of Perilesional Sampling of Patients Undergoing Fusion Prostate Biopsies

Riccardo Lombardo  1 , Giorgia Tema  1 , Antonio Nacchia  1 , Elisa Mancini  1 , Sara Franco  1 , Filippo Zammitti  1 , Antonio Franco  1 , Hannes Cash  2 , Carmen Gravina  1 , Alessio Guidotti  1 , Giacomo Gallo  1 , Nicola Ghezzo  1 , Antonio Cicione  1 , Andrea Tubaro  1 , Riccardo Autorino  3 , Cosimo De Nunzio  1
Affiliations

Role of Perilesional Sampling of Patients Undergoing Fusion Prostate Biopsies

Riccardo Lombardo et al. Life (Basel). .

Abstract

Recently, researchers have proposed perilesional sampling during prostate biopsies to avoid systematic biopsies of patients at risk of prostate cancer. The aim of our study is to evaluate the role of perilesional sampling to avoid systematic biopsies of patients undergoing fusion biopsies. A prospective cohort of patients undergoing transrectal MRI transrectal fusion biopsies were consecutively enrolled. All the patients underwent systematic biopsies (SB), targeted biopsies (TB) and perilesional biopsies within 10 mm from the lesion (PB). The detection rates of different strategies were determined. A total of 262 patients were enrolled. The median age of those enrolled was 70 years. The mean BMI was 27 kg/m2, and the mean and prostate volume was 52 mL. A PIRADS score ≥ 4 was recorded in 163/262 (40%) patients. Overall, the detection rates of cancer were 43.5% (114/262) and 35% (92/262) for csPCa. The use of the target + peri-target strategy resulted in a detection of 32.8% (86/262) of cancer cases and of 29% (76/262) of csPCa cases (Grade Group > 2). Using the target plus peri-target approach resulted in us missing 18/262 (7%) of the csPCa cases, avoiding the diagnosis of 8/262 (3%) of nsPCa cases. A biopsy strategy including lesional and perilesional sampling could avoid unnecessary prostate biopsies. However, the risk of missing significant cancers is present. Future studies should assess the cost-benefit relationship of different strategies.

Keywords: perilesional sampling; prostate biopsy; targeted biopsies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Detection of Cancer and csCancer in different biopsy strategies.
See this image and copyright information in PMC

References

    1. Mottet N., Bellmunt J., Bolla M., Briers E., Cumberbatch M.G., De Santis M., Fossati N., Gross T., Henry A.M., Joniau S., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 2017;71:618–629. doi: 10.1016/j.eururo.2016.08.003. - DOI - PubMed
    1. Siddiqui M.R., Ansbro B., Shah P.V., Aguiar J.A., Li E.V., Rich J.M., Mahenthiran A.K., Moataz S.A.S., Keeter M.-K., Mai Q., et al. Real-world use of MRI for risk stratification prior to prostate biopsy. Prostate Cancer Prostatic Dis. 2022;26:353–359. doi: 10.1038/s41391-022-00543-4. - DOI - PubMed
    1. Kuru T.H., Saeb-Parsy K., Cantiani A., Frey J., Lombardo R., Serrao E., Gaziev G., Koo B., Roethke M., Gnanapragasam V., et al. Evolution of repeat prostate biopsy strategies incorporating transperineal and MRI-TRUS fusion techniques. World J. Urol. 2014;32:945–950. doi: 10.1007/s00345-014-1334-1. - DOI - PubMed
    1. Hsieh P.-F., Li P.-I., Lin W.-C., Chang H., Chang C.-H., Wu H.-C., Chang Y.-H., Wang Y.-D., Huang W.-C., Huang C.-P. Learning Curve of Transperineal MRI/US Fusion Prostate Biopsy: 4-Year Experience. Life. 2023;13:638. doi: 10.3390/life13030638. - DOI - PMC - PubMed
    1. Newman T.H., Stroman L., Hadjipavlou M., Haque A., Rusere J., Chan K., Ioannides D., Di Benedetto A., Pinczes T., Popert R., et al. EXIT from TRansrectal prostate biopsies (TREXIT): Sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy. Prostate Cancer Prostatic Dis. 2021;25:283–287. doi: 10.1038/s41391-021-00438-w. - DOI - PubMed

LinkOut - more resources